nach oben

Erschienen in:

09.12.2022

Reevaluation of cardiovascular risk factors for thrombotic events in 580 Japanese patients with essential thrombocythemia

verfasst von: Chiho Furuya, Yoshinori Hashimoto, Soji Morishita, Tadaaki Inano, Tomonori Ochiai, Shuichi Shirane, Yoko Edahiro, Marito Araki, Miki Ando, Norio Komatsu

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

Risk-adapted therapy is recommended to prevent thrombosis in essential thrombocythemia (ET) patients. An advanced age, a history of thrombosis, and the presence of the JAK2V617F mutation are well-defined risk factors for thrombosis in ET; however, the impact of cardiovascular risk (CVR) factors on thrombosis in ET remains elusive. Therefore, we herein investigated the impact of CVR factors on thrombosis in 580 ET patients who met the 2017 World Health Organization Classification diagnostic criteria. A univariate analysis identified hypertriglyceridemia and multiple CVR factors as strong risk factors for thrombosis (hazard ratio [HR] 3.530, 95% confidence interval [CI] 1.630–7.643, P = 0.001 and HR 3.368, 95% CI 1.284–8.833, P = 0.014, respectively) and hyper-LDL cholesterolemia as a potential risk factor (HR 2.191, 95% CI 0.966–4.971, P = 0.061). A multivariate analysis revealed that hypertriglyceridemia was an independent risk factor for thrombosis (HR 3.364, 95% CI 1.541–7.346, P = 0.002). Furthermore, poor thrombosis-free survival was observed in patients with a serum triglyceride level ≥ 1.2 mmol/L (HR = 2.592, P = 0.026 vs. < 1.2 mmol/L) or two or more CVR factors (P = 0.011 vs. no CVR factors and P = 0.005 vs. one CVR factor). These results revealed the impact of CVR factors on thrombosis in ET. Since CVR factors are manageable, lifestyle interventions, such as the control of serum triglyceride levels, may effectively prevent thrombosis in ET patients.

Nur mit Berechtigung zugänglich

Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R, Reiter A, Cervantes F, Harrison C, Mc Mullin MF, Hasselbalch HC, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G, Kroeger N, Griesshammer M, Birgegard G, Barosi G (2018) Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia 32(5):1057–1069. https://doi.org/10.1038/s41375-018-0077-1CrossRefPubMedPubMedCentral

Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Vannucchi AM, Tefferi A (2012) Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 120 (26):5128–5133; quiz 5252. doi:https://doi.org/10.1182/blood-2012-07-444067

Barbui T, Vannucchi AM, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Finazzi G, Carobbio A, Thiele J, Passamonti F, Falcone C, Tefferi A (2015) Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J 5:e369. https://doi.org/10.1038/bcj.2015.94CrossRefPubMedPubMedCentral

Haider M, Gangat N, Lasho T, Abou Hussein AK, Elala YC, Hanson C, Tefferi A (2016) Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients. Am J Hematol 91(4):390–394. https://doi.org/10.1002/ajh.24293CrossRefPubMed

Tefferi A, Pardanani A (2019) Essential thrombocythemia. N Engl J Med 381(22):2135–2144. https://doi.org/10.1056/NEJMcp1816082CrossRefPubMed

Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, Duffy A, Boyd EM, Bench AJ, Scott MA, Vassiliou GS, Milligan DW, Smith SR, Erber WN, Bareford D, Wilkins BS, Reilly JT, Harrison CN, Green AR, Medical Research Council Adult Leukaemia Working P, Australasian L, Lymphoma G (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 366(9501):1945–1953. https://doi.org/10.1016/S0140-6736(05)67785-9CrossRefPubMed

Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R, Marfisi RM, Finazzi G, Guerini V, Fabris F, Randi ML, De Stefano V, Caberlon S, Tafuri A, Ruggeri M, Specchia G, Liso V, Rossi E, Pogliani E, Gugliotta L, Bosi A, Barbui T, Wp GM (2007) Clinical profile of homozygous JAK2 617V > F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 110(3):840–846. https://doi.org/10.1182/blood-2006-12-064287CrossRefPubMed

Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, Antonioli E, Gisslinger H, Buxhofer-Ausch V, Finazzi G, Gangat N, Tefferi A, Barbui T (2011) Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 117(22):5857–5859. https://doi.org/10.1182/blood-2011-02-339002CrossRefPubMed

Montanaro M, Latagliata R, Cedrone M, Spadea A, Rago A, Di Giandomenico J, Spirito F, Porrini R, De Muro M, Leonetti SC, Villiva N, De Gregoris C, Breccia M, Montefusco E, Santoro C, Cimino G, Majolino I, Mazzucconi MG, Alimena G, Andriani A (2014) Thrombosis and survival in essential thrombocythemia: a regional study of 1,144 patients. Am J Hematol 89(5):542–546. https://doi.org/10.1002/ajh.23685CrossRefPubMed

10.

Hashimoto Y, Nakamae H, Tanaka T, Omura H, Horiuchi M, Yoshimura T, Takakuwa T, Mugitani A, Hirose A, Nakamae M, Koh H, Hino M (2018) Validation of previous prognostic models for thrombosis and exploration of modified models in patients with essential thrombocythemia. Eur J Haematol 101(4):508–513. https://doi.org/10.1111/ejh.13136CrossRefPubMed

11.

Carandang R, Seshadri S, Beiser A, Kelly-Hayes M, Kase CS, Kannel WB, Wolf PA (2006) Trends in incidence, lifetime risk, severity, and 30-day mortality of stroke over the past 50 years. JAMA 296(24):2939–2946. https://doi.org/10.1001/jama.296.24.2939CrossRefPubMed

12.

D’Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB (2008) General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117(6):743–753. https://doi.org/10.1161/CIRCULATIONAHA.107.699579CrossRefPubMed

13.

Kubo M, Hata J, Doi Y, Tanizaki Y, Iida M, Kiyohara Y (2008) Secular trends in the incidence of and risk factors for ischemic stroke and its subtypes in Japanese population. Circulation 118(25):2672–2678. https://doi.org/10.1161/CIRCULATIONAHA.107.743211CrossRefPubMed

14.

Hata J, Ninomiya T, Hirakawa Y, Nagata M, Mukai N, Gotoh S, Fukuhara M, Ikeda F, Shikata K, Yoshida D, Yonemoto K, Kamouchi M, Kitazono T, Kiyohara Y (2013) Secular trends in cardiovascular disease and its risk factors in Japanese: half-century data from the Hisayama Study (1961–2009). Circulation 128(11):1198–1205. https://doi.org/10.1161/CIRCULATIONAHA.113.002424CrossRefPubMed

15.

Cortelazzo S, Viero P, Finazzi G, D’Emilio A, Rodeghiero F, Barbui T (1990) Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 8(3):556–562. https://doi.org/10.1200/JCO.1990.8.3.556CrossRefPubMed

16.

Watson KV, Key N (1993) Vascular complications of essential thrombocythemia—a link to cardiovascular risk-factors. Br J Haematol 83(2):198–203. https://doi.org/10.1111/j.1365-2141.1993.tb08272.xCrossRefPubMed

17.

Ruggeri M, Finazzi G, Tosetto A, Riva S, Rodeghiero F, Barbui T (1998) No treatment for low-risk thrombocythaemia: results from a prospective study. Brit J Haematol 103(3):772–777CrossRef

18.

Besses C, Cervantes F, Pereira A, Florensa L, Sole F, Hernandez-Boluda JC, Woessner S, Sans-Sabrafen J, Rozman C, Montserrat E (1999) Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia 13(2):150–154. https://doi.org/10.1038/sj.leu.2401270CrossRefPubMed

19.

Bazzan M, Tamponi G, Schinco P, Vaccarino A, Foli C, Gallone G, Pileri A (1999) Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia. Ann Hematol 78(12):539–543. https://doi.org/10.1007/s002770050555CrossRefPubMed

20.

Jantunen R, Juvonen E, Ikkala E, Oksanen K, Anttila P, Ruutu T (2001) The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia. Ann Hematol 80(2):74–78. https://doi.org/10.1007/s002770000244CrossRefPubMed

21.

Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A (2006) Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 81(2):159–166. https://doi.org/10.4065/81.2.159CrossRefPubMed

22.

Radaelli F, Colombi M, Calori R, Zilioli VR, Bramanti S, Iurlo A, Zanella A (2007) Analysis of risk factors predicting thrombotic and/or haemorrhagic complications in 306 patients with essential thrombocythemia. Hematol Oncol 25(3):115–120. https://doi.org/10.1002/hon.816CrossRefPubMed

23.

Fu R, Xuan M, Lv C, Zhang L, Li H, Zhang X, Zhang D, Sun T, Xue F, Liu X, Liang H, Zhang L, Yang R (2014) External validation and clinical evaluation of the International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in a large cohort of Chinese patients. Eur J Haematol 92(6):502–509. https://doi.org/10.1111/ejh.12275CrossRefPubMed

24.

Lekovic D, Gotic M, Milic N, Miljic P, Mitrovic M, Cokic V, Elezovic I (2014) The importance of cardiovascular risk factors for thrombosis prediction in patients with essential thrombocythemia. Med Oncol 31(10):231. https://doi.org/10.1007/s12032-014-0231-1CrossRefPubMed

25.

Posfai E, Marton I, Kotosz B, Borbenyi Z (2015) Contribution of cardiovascular risk factors in the thrombotic complications of essential thrombocythaemia: a Hungarian single-institute retrospective analysis. Eur Rev Med Pharmacol Sci 19(7):1258–1263PubMed

26.

Accurso V, Santoro M, Mancuso S, Contrino AD, Casimiro P, Sardo M, Raso S, Di Piazza F, Perez A, Bono M, Russo A, Siragusa S (2020) Cardiovascular risk in essential thrombocythemia and polycythemia vera: thrombotic risk and survival. Mediterr J Hematol Infect Dis 12(1):e2020008. https://doi.org/10.4084/MJHID.2020.008CrossRefPubMedPubMedCentral

27.

Zhang YH, Zhou Y, Wang YS, Teng GS, Li DP, Wang Y, Du CX, Chen YF, Zhang HQ, Li YQ, Fu LX, Chen KY, Bai J (2020) Thrombosis among 1537 patients with JAK2(V617F)-mutated myeloproliferative neoplasms: risk factors and development of a predictive model. Cancer Med-Us 9(6):2096–2105. https://doi.org/10.1002/cam4.2886CrossRef

28.

Hashimoto Y, Ito T, Gotoh A, Nakamae M, Kimura F, Koike M, Kirito K, Wada H, Usuki K, Tanaka T, Mori T, Wakita S, Saito TI, Kada A, Saito AM, Shimoda K, Sugimoto Y, Kurokawa T, Tomita A, Edahiro Y, Akashi K, Matsumura I, Takenaka K, Komatsu N (2022) Clinical characteristics, prognostic factors, and outcomes of patients with essential thrombocythemia in Japan: the JSH‑MPN‑R18 study. International Journal of Hematology 115

29.

Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405. https://doi.org/10.1182/blood-2016-03-643544CrossRefPubMed

30.

Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (2017) WHO classification of tumours of haematopoietic and lymphoid tissues. World Health Organization classification of tumours, rev. 4th ed edn. International Agency for Research on Cancer.

31.

Morishita S, Komatsu N, Kirito K, Koda AH, Sekiguchi Y, Tsuneda S, Noda N (2011) Alternately binding probe competitive PCR as a simple, cost-effective, and accurate quantification method for JAK2V617F allele burden in myeloproliferative neoplasms. Leukemia Res 35(12):1632–1636. https://doi.org/10.1016/j.leukres.2011.06.016CrossRef

32.

Misawa K, Yasuda H, Araki M, Ochiai T, Morishita S, Shirane S, Edahiro Y, Gotoh A, Ohsaka A, Komatsu N (2018) Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms. Int J Hematol 107(6):673–680. https://doi.org/10.1007/s12185-018-2421-7CrossRefPubMed

33.

Authors/Task Force M, Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Z, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL (2016) 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 253:281–344. https://doi.org/10.1016/j.atherosclerosis.2016.08.018CrossRef

34.

Kanda Y (2013) Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transpl 48(3):452–458. https://doi.org/10.1038/bmt.2012.244CrossRef

35.

Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW, Eddleman KM, Jarrett NM, LaBresh K, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF, American College of Cardiology/American Heart Association Task Force on Practice G (2014) 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129(25 Suppl 2):S1-45. https://doi.org/10.1161/01.cir.0000437738.63853.7aCrossRefPubMed

36.

Nishimura K, Okamura T, Watanabe M, Nakai M, Takegami M, Higashiyama A, Kokubo Y, Okayama A, Miyamoto Y (2016) Predicting coronary heart disease using risk factor categories for a Japanese urban population, and comparison with the Framingham risk score: the Suita study. J Atheroscler Thromb 23(9):1138–1139. https://doi.org/10.5551/jat.Er19356CrossRefPubMed

37.

Iso H, Sato S, Kitamura A, Imano H, Kiyama M, Yamagishi K, Cui R, Tanigawa T, Shimamoto T (2007) Metabolic syndrome and the risk of ischemic heart disease and stroke among Japanese men and women. Stroke 38(6):1744–1751. https://doi.org/10.1161/STROKEAHA.106.469072CrossRefPubMed

38.

Toth PP, Philip S, Hull M, Granowitz C (2019) Hypertriglyceridemia is associated with an increased risk of peripheral arterial revascularization in high-risk statin-treated patients: a large administrative retrospective analysis. Clin Cardiol 42(10):908–913. https://doi.org/10.1002/clc.23241CrossRefPubMedPubMedCentral

39.

Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG (2008) Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 300(18):2142–2152. https://doi.org/10.1001/jama.2008.621CrossRefPubMed

40.

Wang TT, Xu J, Fu L, Li L (2020) Hypertriglyceridemia is associated with platelet hyperactivation in metabolic syndrome patients. Int J Clin Pract 74(7). ARTN e13508. https://doi.org/10.1111/ijcp.13508

41.

Iso H, Imano H, Yamagishi K, Ohira T, Cui R, Noda H, Sato S, Kiyama M, Okada T, Hitsumoto S, Tanigawa T, Kitamura A, Investigators C (2014) Fasting and non-fasting triglycerides and risk of ischemic cardiovascular disease in Japanese men and women: the Circulatory Risk in Communities Study (CIRCS). Atherosclerosis 237(1):361–368. https://doi.org/10.1016/j.atherosclerosis.2014.08.028CrossRefPubMed

Titel: Reevaluation of cardiovascular risk factors for thrombotic events in 580 Japanese patients with essential thrombocythemia
verfasst von: Chiho Furuya
Yoshinori Hashimoto
Soji Morishita
Tadaaki Inano
Tomonori Ochiai
Shuichi Shirane
Yoko Edahiro
Marito Araki
Miki Ando
Norio Komatsu
Publikationsdatum: 09.12.2022
Verlag: Springer US
Erschienen in: Journal of Thrombosis and Thrombolysis / Ausgabe 2/2023
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-022-02751-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

SGLT2-Inhibitoren und GLP-1-Rezeptoragonisten im Schlagabtausch

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Wer hat die Nase vorn – SGLT2-Inhibitoren oder GLP-1-Rezeptoragonisten? Diese Frage diskutierten zwei Experten in einer Session auf dem diesjährigen Diabetes-Kongress.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Delir bei kritisch Kranken – Antipsychotika versus Placebo

16.05.2024 Delir nicht substanzbedingt Nachrichten

Um die Langzeitfolgen eines Delirs bei kritisch Kranken zu mildern, wird vielerorts auf eine Akuttherapie mit Antipsychotika gesetzt. Eine US-amerikanische Forschungsgruppe äußert jetzt erhebliche Vorbehalte gegen dieses Vorgehen. Denn es gibt neue Daten zum Langzeiteffekt von Haloperidol bzw. Ziprasidon versus Placebo.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2023

External validation of the ADA score for predicting thrombosis among acutely ill hospitalized medical patients from the APEX Trial

Clinical impact of oral anticoagulation among octogenarians with atrial fibrillation and anaemia

Evaluation of the effect of eltrombopag therapy on the platelet collagen receptor glycoprotein VI (GPVI) expression and soluble GPVI levels in young patients with immune thrombocytopenia

Perioperative continuous infusions of factor VIII versus factor IX for patients with hemophilia A or B undergoing major surgery

Could PD-L1 positivity be associated with venous thrombosis in patients with non-small cell lung cancer?